Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model

Danielle N. Renner, Courtney S. Malo, Fang Jin, Ian F Parney, Kevin D. Pavelko, Aaron J. Johnson

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The addition of antiangiogenic therapy to the standard-of-care treatment regimen for recurring glioblastoma has provided some clinical benefits while also delineating numerous caveats, prompting evaluation of the elicited alterations to the tumor microenvironment. Of critical importance, given the steadily increasing incorporation of immunotherapeutic approaches clinically, is an enhanced understanding of the interplay between angiogenic and immune response pathways within tumors. In the present study, the GL261 glioma mouse model was used to determine the effects of antiangiogenic treatment in an immune-competent host. Following weekly systemic administration of aflibercept, an inhibitor of vascular endothelial growth factor, tumor volume was assessed by magnetic resonance imaging and changes to the tumor microenvironment were determined. Treatment with aflibercept resulted in reduced tumor burden and increased survival compared with controls. Additionally, decreased vascular permeability and preservation of the integrity of tight junction proteins were observed. Treated tumors also displayed hallmarks of anti-angiogenic evasion, including marked upregulation of vascular endothelial growth factor expression and increased tumor invasiveness. Aflibercept was then administered in combination with a picornavirus-based antitumor vaccine and tumor progression was evaluated. This combination therapy significantly delayed tumor progression and extended survival beyond that observed for either therapy alone. As such, this work demonstrates the efficacy of combined antiangiogenic and immunotherapy approaches for treating established gliomas and provides a foundation for further evaluation of the effects of antiangiogenic therapy in the context of endogenous or vaccine-induced inflammatory responses.

Original languageEnglish (US)
Pages (from-to)226-236
Number of pages11
JournalNeurotherapeutics
Volume13
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Picornaviridae
Glioma
Vaccination
Tumor Microenvironment
Tumor Burden
Vascular Endothelial Growth Factor A
Therapeutics
Neoplasms
Tight Junction Proteins
Cancer Vaccines
Capillary Permeability
Glioblastoma
Standard of Care
Immunotherapy
Up-Regulation
Vaccines
Magnetic Resonance Imaging

Keywords

  • Antiangiogenic
  • Combination therapy
  • Glioma
  • Immunotherapy
  • Tumor invasiveness

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Pharmacology

Cite this

Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model. / Renner, Danielle N.; Malo, Courtney S.; Jin, Fang; Parney, Ian F; Pavelko, Kevin D.; Johnson, Aaron J.

In: Neurotherapeutics, Vol. 13, No. 1, 01.01.2016, p. 226-236.

Research output: Contribution to journalArticle

@article{bd1d4ff79a884357b971704184fc287b,
title = "Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model",
abstract = "The addition of antiangiogenic therapy to the standard-of-care treatment regimen for recurring glioblastoma has provided some clinical benefits while also delineating numerous caveats, prompting evaluation of the elicited alterations to the tumor microenvironment. Of critical importance, given the steadily increasing incorporation of immunotherapeutic approaches clinically, is an enhanced understanding of the interplay between angiogenic and immune response pathways within tumors. In the present study, the GL261 glioma mouse model was used to determine the effects of antiangiogenic treatment in an immune-competent host. Following weekly systemic administration of aflibercept, an inhibitor of vascular endothelial growth factor, tumor volume was assessed by magnetic resonance imaging and changes to the tumor microenvironment were determined. Treatment with aflibercept resulted in reduced tumor burden and increased survival compared with controls. Additionally, decreased vascular permeability and preservation of the integrity of tight junction proteins were observed. Treated tumors also displayed hallmarks of anti-angiogenic evasion, including marked upregulation of vascular endothelial growth factor expression and increased tumor invasiveness. Aflibercept was then administered in combination with a picornavirus-based antitumor vaccine and tumor progression was evaluated. This combination therapy significantly delayed tumor progression and extended survival beyond that observed for either therapy alone. As such, this work demonstrates the efficacy of combined antiangiogenic and immunotherapy approaches for treating established gliomas and provides a foundation for further evaluation of the effects of antiangiogenic therapy in the context of endogenous or vaccine-induced inflammatory responses.",
keywords = "Antiangiogenic, Combination therapy, Glioma, Immunotherapy, Tumor invasiveness",
author = "Renner, {Danielle N.} and Malo, {Courtney S.} and Fang Jin and Parney, {Ian F} and Pavelko, {Kevin D.} and Johnson, {Aaron J.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/s13311-015-0407-1",
language = "English (US)",
volume = "13",
pages = "226--236",
journal = "Neurotherapeutics",
issn = "1933-7213",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model

AU - Renner, Danielle N.

AU - Malo, Courtney S.

AU - Jin, Fang

AU - Parney, Ian F

AU - Pavelko, Kevin D.

AU - Johnson, Aaron J.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The addition of antiangiogenic therapy to the standard-of-care treatment regimen for recurring glioblastoma has provided some clinical benefits while also delineating numerous caveats, prompting evaluation of the elicited alterations to the tumor microenvironment. Of critical importance, given the steadily increasing incorporation of immunotherapeutic approaches clinically, is an enhanced understanding of the interplay between angiogenic and immune response pathways within tumors. In the present study, the GL261 glioma mouse model was used to determine the effects of antiangiogenic treatment in an immune-competent host. Following weekly systemic administration of aflibercept, an inhibitor of vascular endothelial growth factor, tumor volume was assessed by magnetic resonance imaging and changes to the tumor microenvironment were determined. Treatment with aflibercept resulted in reduced tumor burden and increased survival compared with controls. Additionally, decreased vascular permeability and preservation of the integrity of tight junction proteins were observed. Treated tumors also displayed hallmarks of anti-angiogenic evasion, including marked upregulation of vascular endothelial growth factor expression and increased tumor invasiveness. Aflibercept was then administered in combination with a picornavirus-based antitumor vaccine and tumor progression was evaluated. This combination therapy significantly delayed tumor progression and extended survival beyond that observed for either therapy alone. As such, this work demonstrates the efficacy of combined antiangiogenic and immunotherapy approaches for treating established gliomas and provides a foundation for further evaluation of the effects of antiangiogenic therapy in the context of endogenous or vaccine-induced inflammatory responses.

AB - The addition of antiangiogenic therapy to the standard-of-care treatment regimen for recurring glioblastoma has provided some clinical benefits while also delineating numerous caveats, prompting evaluation of the elicited alterations to the tumor microenvironment. Of critical importance, given the steadily increasing incorporation of immunotherapeutic approaches clinically, is an enhanced understanding of the interplay between angiogenic and immune response pathways within tumors. In the present study, the GL261 glioma mouse model was used to determine the effects of antiangiogenic treatment in an immune-competent host. Following weekly systemic administration of aflibercept, an inhibitor of vascular endothelial growth factor, tumor volume was assessed by magnetic resonance imaging and changes to the tumor microenvironment were determined. Treatment with aflibercept resulted in reduced tumor burden and increased survival compared with controls. Additionally, decreased vascular permeability and preservation of the integrity of tight junction proteins were observed. Treated tumors also displayed hallmarks of anti-angiogenic evasion, including marked upregulation of vascular endothelial growth factor expression and increased tumor invasiveness. Aflibercept was then administered in combination with a picornavirus-based antitumor vaccine and tumor progression was evaluated. This combination therapy significantly delayed tumor progression and extended survival beyond that observed for either therapy alone. As such, this work demonstrates the efficacy of combined antiangiogenic and immunotherapy approaches for treating established gliomas and provides a foundation for further evaluation of the effects of antiangiogenic therapy in the context of endogenous or vaccine-induced inflammatory responses.

KW - Antiangiogenic

KW - Combination therapy

KW - Glioma

KW - Immunotherapy

KW - Tumor invasiveness

UR - http://www.scopus.com/inward/record.url?scp=84955401892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955401892&partnerID=8YFLogxK

U2 - 10.1007/s13311-015-0407-1

DO - 10.1007/s13311-015-0407-1

M3 - Article

C2 - 26620211

AN - SCOPUS:84955401892

VL - 13

SP - 226

EP - 236

JO - Neurotherapeutics

JF - Neurotherapeutics

SN - 1933-7213

IS - 1

ER -